Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey
HEPATOLOGY INTERNATIONAL, cilt.11, sa.6, ss.509-516, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 11 Sayı: 6
- Basım Tarihi: 2017
- Doi Numarası: 10.1007/s12072-017-9820-3
- Dergi Adı: HEPATOLOGY INTERNATIONAL
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.509-516
- Anahtar Kelimeler: HCV, Economic impact, Cost-effectiveness, Treatment, WHO Targets, GENOTYPE 1 INFECTION, UNITED-STATES, LIVER-DISEASE, RISK-FACTORS, HCV, SOFOSBUVIR, LEDIPASVIR, VIRUS, RIBAVIRIN, ABT-450/R-OMBITASVIR
- Ankara Üniversitesi Adresli: Evet
Özet
Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.